Hightide Biopharma Pty Ltd

This study tested an experimental drug called HTD1801 in 408 adults with type 2 diabetes whose blood sugar was still too high despite diet and exercise. Participants received either the drug or a placebo for 24 weeks. The main goal was to see if the drug could lower average blood…

This study tested an experimental drug called HTD1801 in 59 adults with primary sclerosing cholangitis (PSC), a rare liver disease. Participants received either a low dose, a high dose, or a placebo for 18 weeks. The main goal was to see if the drug could lower a key liver enzyme…

This study tested a new drug called HTD1801 in 551 adults with type 2 diabetes whose blood sugar was not well controlled by metformin alone. Participants received either HTD1801 or a placebo for 24 weeks. The main goal was to see if the drug could lower blood sugar levels (HbA1c)…

This study tested a new medicine called HTD1801 in 367 adults with type 2 diabetes whose blood sugar was not well controlled with metformin alone. The goal was to see if HTD1801 works as well as or better than a common drug, dapagliflozin, at lowering blood sugar over 24 weeks. P…